Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilars

Rheumatology Advocacy in 2019

Angus B. Worthing, MD, FACP, FACR  |  

A belated Happy New Year to my fellow advocates! Here’s your first update for 2019 on what the rheumatology community should know is going on in Washington, D.C., right now. Current Climate On Jan. 3, the 116th Congress gaveled into session with Democrats in control of the House of Representatives and Republicans still the majority in the…

Gearing Up for State Legislation in 2019: 5 Issues that Need Your Attention

  |  

With a number of new legislators and new governors sworn in this month, 2019 promises to be an exciting year for state-level rheumatology advocacy. “Now is the time to reach out and share our top issues with new legislators in your state,” suggests Joseph Cantrell, ACR senior manager of state affairs. 2019 Priorities ACR Affiliate…

ACR Leaders Discuss E/M Coding Changes, Step Therapy & More

  |  

CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…

Committee on Rheumatologic Care Helps Establish Principles & Position Statements

  |  

The ACR’s Committee on Rheumatologic Care (CORC) has been busy on many fronts, including establishing new position statements for the College, introducing new practice perspectives and engaging multiple stakeholders in actions to protect and enhance rheumatology practice, such as with payers. “CORC ensures the rheumatology voice is heard in all of the most critical venues,”…

2018 ACR Awards of Distinction & ACR Masters

  |  

CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. You’ll also find the 2018 Masters list. In the next issue,…

ACR Leaders Outline Advocacy Victories, Threats

Thomas R. Collins  |  

CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…

8 Ways to Help Your Patients with Medication Costs

  |  

A patient with rheumatoid arthritis (RA) comes to your office and needs a medication. You prescribe it, and the patient’s insurance plan covers it. The patient begins the medication and slowly but surely feels better. Prescribing drugs for a patient should be this simple but rarely is, thanks to the high cost of drugs and…

RISE Lifts Research: The 2018 Annual Meeting Features 6 New Studies Based on RISE Data

  |  

Data from the ACR’s Rheumatology Informatics System for Effectiveness (RISE) were used by rheumatology researchers in a crop of new studies that will be presented at the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Six abstracts, including four oral and two poster presentations, were accepted for this year’s meeting. They explore topics ranging from…

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

  |  

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…